| http://www.w3.org/ns/prov#value | - Treatment with other DMARDs and biologics, such as the drugs of the anti-TNF class, and mainly with the IL-6 receptor inhibitor (tocilizumab) have controlled inflammation and increased the previously reduced HDL and TC associated with inflammation, without interfering with the atherosclerotic index (TC/HDL), and without increasing clinical cardiovascular events so far.42-45 In page 493:
|
